Analysis of the Antimicrobial Market in Pakistan: Is It Really Necessary Such a Vast Offering of “Watch” Antimicrobials?

• Main Authors: Farrukh Malik, Albert Figueras
• Format: Article
• Language: English
• Published: MDPI AG 2019-10-01
• Series: Antibiotics
• Subjects: antimicrobial market; irrational drug use; aware; pharmacovigilance; antibiotic consumption; pakistan
• Online Access: https://www.mdpi.com/2079-6382/8/4/189

Understanding antimicrobials (AM) on offer in a pharmaceutical market, with a particular reference to drugs categorized as “Watch” active ingredients, is one of the important first steps to prevent their potentially inappropriate use. The March 2019 data of all AM containing registered brands and presentations currently being sold in the country for the J01 Anatomical Therapeutic Chemical (ATC) subgroup from IQVIA Pakistan was used. Each AM was categorized as “Access,” “Watch,” or “Reserve,” according to the WHO AWaRe classification. There were 59 single chemical entities and 14 combinations with 1869 brands and 4648 presentations. The WHO Essential Medicines List included 35 J01 AM while an additional 38 single and combination AM with 425 brands and 977 presentations were present in the country. Looking at the whole list of marketed AM, 8 of the 10 AM with more than 60 brands were classified as “Watch”, offering 962 brands and 2418 presentations. Most AM marketed in Pakistan, of which there are an excessive number of brands, belong to the “Watch” AWaRe category. The higher the number of brands, the higher the marketing pressure on prescribers and pharmacists will be which implies more potential confusion. One vital step to rationalize the use of AM lies in reviewing their market offer.